Related Experiment Videos
Allogeneic stem cell transplantation for chronic myeloid leukemia
1Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Seminars in Hematology
|February 4, 2003
Summary
Allogeneic stem cell transplantation (SCT) offers a cure for chronic myeloid leukemia (CML) by leveraging the graft-versus-leukemia effect. This review details SCT
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Allogeneic stem cell transplantation (SCT) is crucial for chronic myeloid leukemia (CML) due to its curative potential.
- CML is highly responsive to the graft-versus-leukemia (GVL) effect, making it a key area for GVL research.
Purpose of the Study:
- To review the mechanism of cure for CML using SCT.
- To discuss current SCT outcomes, prognostic factors, and management of relapsed disease.
- To highlight recent advancements in CML transplantation.
Main Methods:
- Literature review of SCT in CML.
- Analysis of GVL effect and minimal residual disease monitoring.
- Synthesis of data on transplantation outcomes and treatment advances.
Main Results:
- SCT is the only established curative treatment for CML.
- GVL effect and minimal residual disease monitoring are critical in CML SCT.
- Various factors influence transplantation outcomes.
Conclusions:
- Allogeneic SCT remains a cornerstone therapy for CML.
- Understanding GVL and monitoring residual disease optimizes SCT efficacy.
- Ongoing research advances CML treatment strategies.